3-氨基-5-(三氟甲基)苯甲酰胺 | 20566-95-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-5-(三氟甲基)苯甲酰胺
• 英文名称: 3-carboxamide-5-trifluoromethylaniline
• 英文别名: (3-amino-5-trifluoromethyl)-benzamide；3-Amino-5-(trifluoromethyl)benzamide
• CAS: 20566-95-4
• 化学式: C₈H₇F₃N₂O
• 分子量: 204.152
• InChiKey: WOSFZFTWHRLVMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-氨基-5-(三氟甲基)苯甲酰胺 、 2-氯-4-(三氟甲基)吡啶-5-羰酰氯 在 Amberlyst A-21 ion-exchange resin 作用下， 以 乙酸乙酯 为溶剂， 反应 0.3h， 以55%的产率得到2-Chloro-4-trifluoromethyl-pyrimidine-5-carboxylic acid (3-carbamoyl-5-trifluoromethyl-phenyl)-amide
  参考文献：
  名称：

  2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3‘,5‘-bis(trifluoromethyl)phenyl)- carboxamide:  A Potent Inhibitor of NF-κB- and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry

  摘要：

  Described is the identification of a novel series of compounds that blocks the activation of two key transcription factors, AP-1 and NF-kB. These transcription factors regulate the expression of several critical proinflammatory proteins and cytokines and represent attractive targets for drug discovery. Through the use of high throughput screening and solution-phase parallel synthesis, inhibitors of both NF-kB and AP-1 were identified. In subsequent testing, these compounds were also shown to block both IL-2 and IL-8 levels in the same cells. One of the most potent compounds in this series, 28, was active in several animal models of inflammation and immunosuppression, thus validating the importance of AP-1 and NF-kB as potential therapeutic targets. The synthesis and preliminary structure-activity relationships of these compounds is addressed.

  DOI：

  10.1021/jm970671g
• 作为产物：
  描述：

  (3-硝基-5-三氟甲基)-苯甲酰胺 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 3-氨基-5-(三氟甲基)苯甲酰胺
  参考文献：
  名称：

  2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3‘,5‘-bis(trifluoromethyl)phenyl)- carboxamide:  A Potent Inhibitor of NF-κB- and AP-1-Mediated Gene Expression Identified Using Solution-Phase Combinatorial Chemistry

  摘要：

  Described is the identification of a novel series of compounds that blocks the activation of two key transcription factors, AP-1 and NF-kB. These transcription factors regulate the expression of several critical proinflammatory proteins and cytokines and represent attractive targets for drug discovery. Through the use of high throughput screening and solution-phase parallel synthesis, inhibitors of both NF-kB and AP-1 were identified. In subsequent testing, these compounds were also shown to block both IL-2 and IL-8 levels in the same cells. One of the most potent compounds in this series, 28, was active in several animal models of inflammation and immunosuppression, thus validating the importance of AP-1 and NF-kB as potential therapeutic targets. The synthesis and preliminary structure-activity relationships of these compounds is addressed.

  DOI：

  10.1021/jm970671g

文献信息

• [EN] PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS<br/>[FR] COMPOSES DE PYRADAZINE UTILES COMME INHIBITEURS DE GSK-3
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004035588A1

  公开（公告）日：2004-04-29

  The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds according to formula (I) and methods of their use.

  本发明通常涉及激酶抑制剂，如GSK3，更具体地涉及根据式(I)的融合吡啶并嘧啶化合物及其使用方法。
• Pyrimidine carboxamides and related compounds and methods for treating
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US05811428A1

  公开（公告）日：1998-09-22

  Compounds having utility as antinflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine- or pyrazine-containing compounds and, in one embodiment, are carboxyamides of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.

  本发明揭示了作为抗炎药物一般以及更具体地用于预防和/或治疗免疫炎症性和自身免疫性疾病的有用化合物。这些化合物是含有嘧啶或吡嗪的化合物，在一个实施例中，它们是相同的羧酰胺。还揭示了通过向需要的动物投与本发明化合物的有效量，优选地以药物组合物的形式，来预防和/或治疗炎症性疾病的方法。
• Pyradazine compounds as gsk-3 inhibitors
  申请人：Dickerson Howard Scott

  公开号：US20060069097A1

  公开（公告）日：2006-03-30

  The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use.

  本发明通常涉及抑制激酶的抑制剂，例如GSK3，更具体地涉及融合嘧啶二氮杂环化合物及其使用方法。
• Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases
  申请人：Bold Guido

  公开号：US20080312192A1

  公开（公告）日：2008-12-18

  The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumour diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N′-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N′-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N′-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.

  本发明涉及利用二芳基脲衍生物制造药物组合物，用于治疗RET依赖性疾病，特别是RET依赖性肿瘤疾病。本发明还涉及新的N-[4-(嘧啶-4-氧基)-苯基]-N'-苯基脲衍生物及其在动物或人体内治疗蛋白激酶依赖性疾病，特别是增殖性疾病，如肿瘤疾病方面的用途。此外，本发明还涉及包含这种新的N-[4-(嘧啶-4-氧基)-苯基]-N'-苯基脲衍生物的药物组合物，以及利用这种新的N-[4-(嘧啶-4-氧基)-苯基]-N'-苯基脲衍生物制备用于治疗蛋白激酶依赖性疾病，特别是增殖性疾病，如肿瘤疾病的药物组合物的用途。
• Monoazoverbindungen enthaltend mindestens eine Carbonamidgruppe
  申请人：CIBA-GEIGY AG

  公开号：EP0162806B1

  公开（公告）日：1989-01-25